1. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam
- Author
-
Quang Minh Vo, Thanh Thi Thanh Tran, Dung Thanh Nguyen, Hung Mạnh Le, Motiur Rahman, Phuong T. Le, Jeremy N. Day, and Ngoc My Nghiem
- Subjects
RNA viruses ,Sofosbuvir ,Hepacivirus ,medicine.disease_cause ,Chi Square Tests ,Gastroenterology ,Geographical Locations ,chemistry.chemical_compound ,Mathematical and Statistical Techniques ,Pegylated interferon ,Genotype ,Medicine and Health Sciences ,Medicine ,Pathology and laboratory medicine ,Multidisciplinary ,Hepatitis C virus ,Pharmaceutics ,Liver Diseases ,Statistics ,Middle Aged ,Viral Load ,Medical microbiology ,Treatment Outcome ,Infectious Diseases ,Vietnam ,Cirrhosis ,Viruses ,Physical Sciences ,Pathogens ,Uridine Monophosphate ,Viral load ,Research Article ,medicine.drug ,Ledipasvir ,medicine.medical_specialty ,Asia ,Daclatasvir ,Science ,Gastroenterology and Hepatology ,Research and Analysis Methods ,Antiviral Agents ,Microbiology ,Drug Therapy ,Virology ,Internal medicine ,Ribavirin ,Humans ,Statistical Methods ,Statistical Hypothesis Testing ,Retrospective Studies ,Fluorenes ,Treatment Guidelines ,Health Care Policy ,Flaviviruses ,business.industry ,Organisms ,Viral pathogens ,Biology and Life Sciences ,Hepatitis C, Chronic ,Hepatitis viruses ,Microbial pathogens ,Health Care ,chemistry ,Co-Infections ,People and Places ,Benzimidazoles ,business ,Viral Transmission and Infection ,Mathematics - Abstract
Background: Hepatitis C virus (HCV) genotype 6 is the commonest cause of chronic hepatitis C infection in much of southeast Asia, but data on the effectiveness of direct-acting antiviral agents (DAAs) against this genotype are limited. We conducted a retrospective cohort study of patients attending the Hospital for Tropical Diseases (HTD), Ho Chi Minh City, Vietnam, to define the effectiveness of DAAs in the treatment of chronic HCV genotype 6 in actual practice. Methods: We included all patients with genotype 6 infections attending our hospital between March 2016 and October 2017 who received treatment with sofosbuvir-based DAA treatment regimens, and compared their responses with those with genotype 1 infections. Results: 1758 patients (1148 genotype 6, 65.4%; 610 genotype 1, 34.6%) were analyzed. The majority of patients (1480, 84.2%) received sofosbuvir/ledipasvir (SOF/LDV) ± ribavirin (RBV); 278 (15.8%) received sofosbuvir/Daclatasvir (SOF/DCV) ± RBV. The median age of the patients was 57 years, (interquartile range (IQR) 46–64 years) The baseline HCV viral load (log IU/ml) was significantly higher in patients infected with genotype 6 compared with those infected with genotype 1 (6.8, 5.3–6.6 versus 6.3, 5.3–6.5 log10 IU/ml, p = Conclusions: Our study suggests that patients with HCV genotype 6 infection in Vietnam may respond less well to treatment with sofosbuvir based DAAs than patients with genotype 1 infections. Further studies are needed to confirm this observation and to define whether it is driven by genotype-specific mutations.
- Published
- 2020